Business Wire

CA-PATIENT-SAFETY

4.4.2022 14:02:12 CEST | Business Wire | Press release

Share
Patient Safety Movement Foundation Announces Dates and Speaker Line-up for 8th Annual World Patient Safety, Science & Technology Summit

The Patient Safety Movement Foundation (PSMF) will host the 8th annual World Patient Safety, Science and Technology Summit (WPSSTS) virtually April 29 and April 30, 2022. The event is co-convened by the American Society of Anesthesiologists, the European Society of Anesthesiology and Intensive Care, the International Society for Quality in Health Care and the World Federation of Societies of Anaesthesiologists. Creating a powerful forum for industry leaders and healthcare organizations to confront leading patient safety issues with actionable ideas and innovations to transform the continuum of care, the event supports PSMF’s mission to reach zero preventable patient harm and death across the world by 2030.

“The last two years have been taxing on the healthcare sector to say the least. The global pandemic placed relentless stress on health systems and medical personnel, which resulted in an increase in preventable medical errors,” said Dr. Michael Ramsay, CEO of PSMF. “Our organization is eager to bring key stakeholders together to help develop solutions to dramatically improve patient safety and eliminate preventable patient harm and death.”

The summit will include a fireside chat with patient safety luminaries, seven keynote addresses, as well as five panel sessions covering various topics in patient safety led by esteemed healthcare leaders. This year’s WPSSTS sessions focus on key issues impacting the healthcare industry, including:

  • Overcoming Obstacles for Applying High Reliability Principles in Healthcare
  • Embracing the Science of Human Factors to Unleash Safety Innovation in Healthcare
  • Patient Advocacy: The Compass for Innovation
  • How Regulation Can Support Quality and Value in Healthcare
  • Healthcare Safety During the Pandemic

Attendees will have the opportunity to network with top hospital executives, patients and family members who have been impacted by medical error, public policymakers and government officials, as well as leaders across the healthcare continuum. Keynote speakers include:

  • Randall Clark, MD, FASA, president of the American Society of Anesthesiologists
  • Edoardo de Robertis, MD, PhD and president of the European Society of Anaesthesiology and Intensive Care (ESAIC)
  • Neelam Dhingra-Kumar, MD, unit head of the WHO Patient Safety Flagship
  • Carsten Engel, MD, CEO of the International Society for Quality in Health Care
  • Joe Kiani, founder & immediate past chairman of the Patient Safety Movement Foundation, as well as founder, chairman & CEO of Masimo
  • Peter Pronovost, MD, PhD, chief clinical transformation officer at University Hospitals
  • Thomas Zeltner MD, chairman of the WHO Foundation, Geneva (Switzerland) and deputy chair of the University Council of the Medical University of Vienna (Austria)

The summit is open to anyone interested in actively planning solutions around the leading patient safety challenges that cause preventable patient deaths in hospitals and healthcare organizations worldwide. Discounted registration is offered for students, patients and family members. To register for the 2022 WPSSTS or to learn more about the event, visit: https://patient.sm/WPSSTS .

About the Patient Safety Movement Foundation: The Patient Safety Movement Foundation (PSMF), a global non-profit organization founded in 2012, is celebrating 10 years of bringing awareness and creating action to eliminate preventable medical errors. Some estimates predict that one in 12 patients are impacted by a preventable medical error, but that number could be even higher as there is no central database tracking these figures in most countries, including the U.S. Over the last decade, there had been major strides to improve patient safety, but the COVID-19 pandemic stressed the system and it proved not to be resilient and took a step backwards. PSMF has a vision to eliminate preventable patient harm and death across the globe by 2030 – and that starts with raising awareness of this critical issue. It unites patients, advocates, health workers, medical technology companies, government, employers and private payers in support of this cause. From its evidence-based best practice solutions (Actionable Patient Safety Solutions™) and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .

Link:

ClickThru

Social Media:

https://www.facebook.com/patientsafetymovement/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Newmont Reports 2025 Mineral Reserves of 118.2 Million Gold Ounces and 12.5 Million Tonnes of Copper19.2.2026 22:08:00 CET | Press release

Newmont Corporation (NYSE: NEM, ASX: NGT, PNGX: NEM) (Newmont or the Company) reported gold Mineral Reserves ("reserves") of 118.2 million attributable ounces at the end of 2025 compared to 134.1 million attributable ounces at the end of 2024, mainly driven by the divestment of assets in 2025. Newmont's portfolio includes significant reserves from other metals, including 12.5 million attributable tonnes of copper reserves and 442 million attributable ounces of silver reserves. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219894602/en/ Percentage of Gold Reserves by Jurisdiction "In 2025, Newmont maintained its position of having the industry's largest gold reserve base, declaring 118 million ounces of reserves, representing decades of production life with meaningful upside," said Natascha Viljoen, Newmont's President and Chief Executive Officer. "Through the disciplined application of technical rigor in our leading expl

Unveiling NVIDIA Solution Center: Grid Dynamics’ Family of AI Solutions to Cut Costs for Retail and Manufacturing19.2.2026 22:05:00 CET | Press release

Key Takeaways: Enables enterprises to replace high-cost and recurring SaaS licensing fees with high-performance and cost-efficient NVIDIA-based solutions Offerings are derived from Grid Dynamics’ proven customer solutions and leverage NVIDIA’s technology stack Commercially deployed, with additional customers expressing interest NVIDIA and Grid Dynamics jointly presented these solutions at the National Retail Federation (NRF) conference in January 2026 Learn more in NVIDIA’s published blog Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics), a premier AI transformation partner for the Fortune 1000, today announced the launch of its NVIDIA Solution Center. This suite of ready-to-deploy AI applications helps retail and manufacturing enterprises move away from costly, recurring SaaS licenses and subscription fees toward high-performance, NVIDIA-powered solutions. Learn more by reading NVIDIA’s recent announcement. The NVIDIA Solution Center is derived from Grid Dynamics’ proven suc

Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results19.2.2026 22:01:00 CET | Press release

Fourth Quarter and Full Year 2025 Financial Highlights Include:Remaining Performance Obligations (RPO) of $652.9 million, up 11.1% from the prior yearAdjusted Calculated Billings, full year 2025, up 4.2% from the prior yearAdjusted Annualized Recurring Revenue (ARR) up 3.1% from the prior year Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the 2025 fourth quarter and fiscal year ended December 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219293814/en/ Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results “Our fourth quarter results reflect solid execution and continued accelerating sales growth, adjusted for the Oracle PeopleSoft support and services wind

Ares Management Prices European Direct Lending CLO II at Over €300 Million19.2.2026 18:25:00 CET | Press release

Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the pricing of its second European Direct Lending Collateralized Loan Obligation, Ares European Direct Lending CLO II (“EDL CLO II”), at over €300 million. Consistent with the underlying composition of its predecessor, EDL CLO II is a diversified CLO comprised entirely of directly originated and actively managed loans issued by over 70 middle-market companies predominantly based in Western Europe and primarily operating in resilient industries. The instrument is weighted towards senior-secured floating rate loans and will be rated by S&P and KBRA. Ares believes EDL CLO II is among the first multi-currency middle-market CLOs in Europe. “We are pleased to successfully price our second European Direct Lending CLO in less than 12 months as we continue building on our nearly 20 years of corporate direct lending experience in Europe,” said Michael Dennis, Partner and Co-Head of

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis19.2.2026 18:00:00 CET | Press release

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor (TNF) antagonists, found nearly half (47.3%) of randomized patients achieved primary endpoint of clinical remission at 54 weeksVedolizumab’s safety profile was generally consistent with its known safety profile in adultsResults were presented at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO) Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (UC), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 The results, presented at the 21st Congress of the European Crohn’

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye